| Names | |
|---|---|
| Preferred IUPAC name | N-(4-hydroxyphenyl)acetamide |
| Other names | 4-Acetamidophenol Paracetamol Acetaminophen N-(4-Hydroxyphenyl)acetamide |
| Pronunciation | /ˌpaɪˌhɑːdrɒksiˌfiːnɪl.əˈsɪtəˌmiːd/ |
| Identifiers | |
| CAS Number | 103-90-2 |
| 3D model (JSmol) | `3D model (JSmol)` string for **p-Hydroxyphenylacetamide** (also known as **4-hydroxyacetanilide** or **paracetamol**) is: ``` NC(=O)Cc1ccc(O)cc1 ``` |
| Beilstein Reference | 603954 |
| ChEBI | CHEBI:4641 |
| ChEMBL | CHEMBL112 |
| ChemSpider | 1940 |
| DrugBank | DB00316 |
| ECHA InfoCard | 03b8746a-7e7e-4c38-8fb4-bf778c37c373 |
| EC Number | EC 3.5.1.6 |
| Gmelin Reference | 184873 |
| KEGG | C00823 |
| MeSH | D000082 |
| PubChem CID | 15122 |
| RTECS number | SE2450000 |
| UNII | OM5455YJ7J |
| UN number | 2811 |
| CompTox Dashboard (EPA) | DTXSID4020707 |
| Properties | |
| Chemical formula | C8H9NO2 |
| Molar mass | 151.16 g/mol |
| Appearance | White crystalline powder |
| Odor | Odorless |
| Density | 1.263 g/cm3 |
| Solubility in water | Slightly soluble |
| log P | 0.46 |
| Vapor pressure | 0.000056 hPa (25 °C) |
| Acidity (pKa) | 9.5 |
| Basicity (pKb) | 7.62 |
| Magnetic susceptibility (χ) | -65.0·10⁻⁶ cm³/mol |
| Refractive index (nD) | 1.653 |
| Viscosity | 1.215 mPa·s (25 °C) |
| Dipole moment | 5.6133 D |
| Thermochemistry | |
| Std molar entropy (S⦵298) | 179.0 J·mol⁻¹·K⁻¹ |
| Std enthalpy of formation (ΔfH⦵298) | -344.9 kJ/mol |
| Std enthalpy of combustion (ΔcH⦵298) | -3245 kJ/mol |
| Pharmacology | |
| ATC code | N02BE01 |
| Hazards | |
| Main hazards | Harmful if swallowed. Causes serious eye irritation. Causes skin irritation. |
| GHS labelling | GHS02, GHS07 |
| Pictograms | GHS07 |
| Signal word | Warning |
| Hazard statements | H302: Harmful if swallowed. |
| Precautionary statements | P264, P270, P301+P312, P330, P501 |
| NFPA 704 (fire diamond) | 1-1-0 |
| Flash point | 170°C |
| Autoignition temperature | 410 °C |
| Lethal dose or concentration | LD50 oral rat 375 mg/kg |
| LD50 (median dose) | LD50 (median dose): 1944 mg/kg (Rat, oral) |
| NIOSH | AM228 |
| PEL (Permissible) | Not established |
| REL (Recommended) | 0.5 mg/day |
| Related compounds | |
| Related compounds | Paracetamol Phenacetin Acetanilide |
| Property | Description | Manufacturer Commentary |
|---|---|---|
| Product Name & IUPAC Name |
Product Name: p-Hydroxyphenylacetamide IUPAC Name: 2-(4-hydroxyphenyl)acetamide |
Production documentation routinely uses both trivial and IUPAC names depending on market, end-user sector, and regional standards. Regulatory filings and COAs reference IUPAC to minimize ambiguity. |
| Chemical Formula | C8H9NO2 | Raw material procurement and batch formula calculations, especially in reactor charging, rely on accurate molecular mass derived from the formula. Analytical confirmation of final product composition references the formula during release. |
| Synonyms & Trade Names | 4-(Acetylamino)phenol; 4-Hydroxyacetanilide; Paracetamol (used interchangeably in some pharmaceutical contexts, though strict pharma grades have distinct supply chain controls) | Technical and grade-specific documentation separates synonyms in order to clarify grade specifications. Pharmaceutical applications require explicit traceability and synonym cataloging to prevent mix-ups in multi-grade plants. |
| HS Code & Customs Classification | 2924.29 (Acetamide derivatives; detailed customs code assignments are dependent on final product application, purity, and regional regulatory requirements) | Customs classification decisions integrate grade, packaging, and end-use data directly from manufacturing documentation. Regulatory updates sometimes trigger re-certification of product shipments; customs documentation always maintains batch traceability. |
Production lines for p-Hydroxyphenylacetamide must address raw material selectivity since precursor purity and para orientation consistency directly affect final assay and impurity levels. Sulfation or acetylation route selection considers waste generation, downstream purification, and product recovery efficiency. In-process controls focus on endpoint reaction monitoring, colorimetric impurity detection, and consistency of melting point for solid forms.
Formulation and post-reaction processing are defined by customer application—pharma, veterinary, or industrial—since excipient compatibility and micronization requirements deviate. Warehousing distinguishes between bulk-in-bag, lined drum, and clean-room packaged microbatches based on customer validation protocols.
The release standard for each batch is tightly bound to internal and contractual specifications, often requiring third-party analytical reconciliation in regulated industries. Documentation includes full traceability from starting material acceptance, intermediate checkpoints, and final batch approval.
In standard production, p-Hydroxyphenylacetamide forms as an off-white to pale beige crystalline solid. Variations in crystallinity and color usually reflect grade level, process impurities, or solvent residues. Odor tends to be faint or barely perceptible. Melt and boil points depend on process route, residual solvent content, and downstream purification but typically exhibit a sharp melting profile representative of high-purity grades. Melting range spread or visible discoloration is often an indicator of process deviation or contamination. Bulk density fluctuates with particle size distribution and granulation method, which should align with application—pharma, industrial, or intermediate synthesis.
Chemical stability remains robust under dry, ambient conditions but the product can degrade if exposed to moisture, oxidants, or high temperature. Discoloration or loss of crystallinity occur when excess heat or acidic/basic vapors are present. For storage and formulation, the sensitivity to hydrolysis and oxidation must be considered, particularly for high-purity or pharmaceutical applications.
Solubility profile differs by grade—trace impurities or crystal habit change the dissolution rate in common polar solvents (e.g., ethanol, methanol, DMSO, water). Process solvents selected during synthesis can impact final solubility characteristics and affect ease of downstream formulation. Inconsistent solution clarity or variable residue after dissolution often points to upstream process drift.
Specification targets are aligned by end-use. Standard grades define physical purity, residue on ignition, and color standards. High-purity or pharma grades warrant extra quantitation of trace impurities, moisture content, and particle analysis. If required, specifications are set according to pharmacopeial standards or customer-specific protocols. The concrete specification table is issued per batch and only after comprehensive in-process and final release testing.
Principal impurities derive from incomplete conversion, side-reaction products, or raw material variability. Process solvents, catalyst residues, and byproducts are tracked in QC. Actual impurity thresholds reflect product grade, with pharmaceutical or food-use categories demanding tightest controls. We use established analytical methods to characterize and quantify trace-level impurities and control batch-to-batch uniformity.
Analytical methods include HPLC, GC, titration, KF titration (for moisture), and mass spectrometry. Final quality assessment addresses appearance, assay, trace solvent, and impurity spectrum. Selection of methodology responds to regulatory or customer-driven documentation. Reference standards for method calibration are traceable to certified sources when necessary.
Raw material selection focuses on precursor purity and supplier consistency. For p-Hydroxyphenylacetamide, phenol derivatives and appropriate acylating agents feature as principal feedstocks. Sourcing strategies prioritize consistent assay, low byproduct profile, and documentation support. Batch deviation typically traces back to raw material impurity or freshness.
Synthesis utilizes either direct acetylation of para-hydroxyaniline or corresponding hydroxyphenyl intermediates. Route selection is governed by efficiency, impurity suppression, and ease of purification. Process engineers adjust solvent, temperature, and reagent stoichiometry to control conversion and selectivity. The critical reaction step involves nucleophilic substitution, managed to minimize ortho/para isomerization, oligomer formation, or over-acylation.
Reaction parameters such as temperature ramp, catalyst load, and agitation intensity remain under close observation to keep impurity formation in check. Batch logs record each deviation or adjustment for traceability. Typical downstream purification involves filtration, multiple recrystallizations, and drying under vacuum or inert gas. Recovered mother liquors undergo impurity analysis for process optimization. Each intermediate and final batch is sampled at critical stages for QC checkpoint testing.
Batch release only proceeds after analytical confirmation of both assay and impurity profile against specification. Where applicable, trace-level detection and full documentation are required for regulated industry supply. Batches failing on any critical metric are quarantined and investigated; records detail investigation, corrective action, and root cause remediation.
p-Hydroxyphenylacetamide participates in etherification, esterification, and electrophilic aromatic substitution. Hydroxyl groups support conjugation, allowing further derivatization for custom synthesis. Acetyl moiety can be exchanged via hydrolysis or transacylation, a pathway often exploited for downstream building blocks.
Reactions involving this substrate typically call for neutral or mildly basic conditions to preserve acetyl and phenolic groups. Catalyst choice and solvent system influence selectivity; temperature control is critical for side reaction minimization. Process chemists define exact conditions case by case, depending on targeted downstream derivative or formulation requirement.
Common modifications yield ether, ester, or amide derivatives valuable for specialty chemical synthesis and as intermediates for pharmaceuticals or agrochemicals. The downstream product spectrum and required modifications depend on grade, impurity threshold, and application-specific performance criteria.
Product stability is best preserved in a dry, cool, well-ventilated space. Avoidance of humidity, direct sunlight, and elevated temperature prevents caking, hydrolysis, and discoloration. Gas protection is considered for highly sensitive grades.
High-density polyethylene and amber glass serve for bulk and sample packaging. Metal contamination or reactive interaction is rarely an issue but handled case by case if the customer specifies ultra-purity or low extractable content.
Shelf life varies with grade and packaging. Discoloration, melting profile broadening, or off-odor mark signs of breakdown. Periodic retesting is undertaken for storage beyond twelve to twenty-four months, depending on product grade and regulatory expectation.
Hazard characterization, if required, is completed per region-specific REACH or OSHA guidelines. Classification references the acute toxicity, irritation, and sensitization studies if available or draws from structurally related analogs when complete toxicology isn’t established for this specific compound. Technical grades usually fall under standard laboratory management requirements; pharma grades require detailed trace impurity declaration.
Safety measures focus on dust control, avoidance of skin or eye contact, and engineering controls for occupational exposure. Eye wash stations and particulate filtration support routine handling.
Acute oral, dermal, and inhalation toxicology is reviewed through published datasets or generated internally for regulatory needs. Where numerical LD50 or exposure limits are available, they are communicated on an as-available basis, or referenced to authoritative compendia as required by law.
In industrial settings, standard PPE includes gloves, goggles, and dust mask. Airborne particulate monitoring and hygiene protocols tailor to batch size and packaging configuration. Facilities supplying regulated markets adopt strict batch traceability and incident response to meet customer and regulatory expectations.
Annual production output for p-Hydroxyphenylacetamide remains driven by both installed reactor volume and purification throughput. Plant capacity scales with market demand and periodic maintenance schedules. Seasonal fluctuations—particularly in the second half of each calendar year—shift effective output due to plant turnarounds or environmental restrictions tied to volatile organics and phenol-derived intermediates. Production is carefully balanced to minimize inventory build and avoid off-grade batches, with volume allocations typically adjusted each quarter in response to customer forecasts and raw material sourcing.
Lead time reflects the ongoing batch production regime and in-process testing schedule. For standard industrial grades, lead times range from several working days to multiple weeks, depending on order volume, purification level, and campaign planning. Minimum order quantities are determined by lot homogeneity and transportation constraints. Bulk users often negotiate annual or quarterly supply agreements, which lock in scheduled releases and reduce the risk of overstocking or extended delivery windows.
Standard packaging formats vary according to end-use and purity grade. Bulk packaging typically uses fiber drums, HDPE drums, or intermediate bulk containers. Sensitive grades—requiring trace contaminant control for pharmaceutical or electronic segment—rely on custom-lined drums or double-sealed containers to prevent ingress of water or extraneous ions. Each secondary packaging approach is validated for its effect on material stability and compliance with transport regulations. Packaging selection directly impacts shelf life and cross-contamination risk.
Shipping scheduled according to Incoterms relevant to the customer’s region, with preference for FCA or FOB in major ports. Dangerous goods regulations may apply for certain grades or related phenol derivatives, necessitating UN-approved containers and trained logistics partners. Payment terms reflect historical credit assessment, contract structure, and international risk management; typical terms involve net 30-60 days with established customers, prepayment or letter of credit for new or high-risk buyers.
Primary input cost derives from phenol or p-hydroxyacetophenone, with notable sensitivity to upstream phenol and acetic acid pricing. Price movement in benzene—phenol’s feedstock—triggers parallel swings, given the manufacturing process route. Utilities and solvent recovery contribute downstream to marginal cost, but raw material input stays the dominant determinant. Compliance-driven purification costs for high-purity grades add variable overhead, reflected by fortification of trace metal removal and low-level organic control steps.
Feedstock volatility, regulatory shifts on emissions, and regional outages impact raw material price swings. Market disruptions in China and India have historically caused abrupt step changes owing to linked supply chains. Maintenance incidents, logistics bottlenecks, and environmental audits further influence output—driving spot price divergence between regions, especially for high-need segments like pharma intermediates.
Price gradients reflect clear distinctions between industrial, analytical, and pharmaceutical grades. Purity thresholds, moisture content, and impurity profiles drive complexity and downstream application compatibility. Regulatory-compliant packaging or those required by cGMP or ISO guidelines for drug or electronics uses add cost over basic industrial packaging. Final certification—such as lot traceability, impurity mapping, or third-party release protocols—imposes additional quality assurance costs, visible in the per-kg price difference.
Global supply concentrates in East Asia, with a cluster of high throughput producers in China responsible for the baseline export pool. The rest of Asia and the EU supplement local demand, but output from Western plants usually targets higher-margin, specialty or home-region buyers. Demand tracks closely with pharma, dye, and electronics industries. Overcapacity periods follow expansion of new Chinese plants, but stringent environmental checks can swiftly reverse these surpluses.
In the US and EU, downstream demand correlates to regulated sectors—pharma, agro, and fine chemicals—often specifying more rigorous impurity control. Supply reliability faces additional scrutiny under domestic regulatory frameworks. Japan emphasizes reliability, repeatability, and impurity disclosure, translating to higher acceptance of technical grade differentiation. India, as both end-user and exporter, influences trade flows and pricing by toggling between domestic and international buyers. China, being the largest producer, exerts unmatched influence on global inventory and price setting.
For 2026, continued wide spread in spot-market and contract pricing is likely, hinging on global economic recovery, environmental regulatory stringency, and feedstock market stabilization. If phenol pricing stabilizes and downstream pharma demand maintains post-pandemic levels, moderate price increases across all grades are expected. Disruptions from environmental policy, shipping delays, or raw material shortages could trigger sharp price spikes, especially for high-spec or pharma-certified batches.
Internal cost accounting, market intelligence on raw material trends, purchasing consortium feedback, and aggregated price tracking from industry data providers inform the above analysis. Price forecasting incorporates historical patterns, forward-looking contracts, and observed supply chain bottlenecks.
Policy-driven plant shutdowns in eastern China and renewed local regulations on wastewater have already caused unexpected cutbacks and price increases over recent quarters. Expansion plans in India—aiming to compete on cost for high-volume pharmaceutical applications—may shift the balance if fully realized and regulatory compliance is maintained through commissioning.
Increased enforcement of REACH and equivalent regulations drives up compliance costs in the EU and US; similar green chemical legislation in China is gradually shifting export eligibility for certain grades. Buyers of pharmaceutical and food-contact grades regularly request expanded impurity testing and additional documentation to satisfy evolving global standards.
Producers respond by increasing in-process control and documentation to maintain batch consistency, investing in continuous processes to reduce waste, and broadening raw material qualification to manage supply risks. Where volatility in raw material costs threatens contract stability, suppliers increasingly use raw material cost indexing and multi-source procurement strategies. Active communication with downstream users helps forecast shifts in demand and formulation priorities, with technical data and traceability protocols aligned to the intended application certification path.
p-Hydroxyphenylacetamide finds usage in multiple downstream sectors, including pharmaceutical synthesis, agchem intermediates, specialty chemical formulation, and fine fragrance or dye production. Each field imposes different technical requirements on product purity, impurity profiles, and documentation support, with pharmaceutical and regulated life-science applications demanding more stringent scrutiny versus industrial or tech-grade demands. The responsiveness of this molecule to controlled reactions such as acetylation, amidation, or selective coupling makes grade choice a central determinant for downstream process success and regulatory qualification.
| Application Sector | Typical Grade(s) Used | Principal Performance Criteria |
|---|---|---|
| Pharmaceutical Intermediates | Pharma Grade, High-Purity Grade | Consistent assay, defined impurity set, low residual solvents, complete batch traceability, regulatory audit trail |
| Agrochemical Synthesis | Technical Grade, High-Purity Grade | Defined assay, process suitability, acceptable secondary impurity levels, supply batch consistency |
| Specialty Chemical/Fine Chemicals | Technical Grade, Custom-Adjusted Lots | Assay, color acceptance, solvent profile, purifier compatibility |
| Perfume & Dye Intermediates | Standard Technical Grade | Color, odor, absence of interfering by-product, cost efficiency |
In pharmaceutical or API intermediate supply routes, greater selectivity is applied at each control point, starting with raw precursor qualification, in-process endpoint confirmation, and a finished product release based on well-defined residual solvent and specific impurity thresholds, batch documentation, and full audit records. For major agchem and industrial specialties, technical grades allow broader impurities within process-tolerant limits, often with specified minimum assay and process compatibility assurances instead of pharmaceutical-level record keeping.
Color and odor, though not limiting in all processes, often guide grade selection where downstream appearance or olfactory thresholds are strict, as in colorant or perfumery precursor work. Volatile residues, sometimes accepted in less sensitive applications, call for targeted reduction through purification steps in regulated or catalytic conversions to prevent downstream reactivity. Process consistency controls start from raw material batch standardization, impacting the reproducibility of the active substance—critical for customers with continuous operations or regulatory filing requirements.
Clarify the end use and process requirements. Pharmaceutical, life-science, and any regulated field will likely enforce higher purity, trace documentation, and tighter impurity standards. Bulk synthetic or commodity applications can often utilize more cost-efficient technical variants.
Evaluate whether the application aligns with GMP, ISO, or other regulated production standards. Pharmaceutical and agchem supply chains may need compliance documentation such as DMF support, full traceability, and regulatory filings, which determine eligibility of certain grades.
Review process sensitivity to impurities, trace organics, or secondary components. Typical values depend on grade and customer specification, with final release criteria set by a combination of product route specifications and customer standards. Where a low-level impurity impacts yield, color, or downstream safety, opt for a higher-purity variant substantiated by batch analysis.
Assess the scale of usage and available project funding. High-purity or custom-validated batches prompt higher production and compliance costs. For continuous or large-volume industrial runs, technical grades may offer substantial cost savings if impurity tolerance is feasible for the application.
Source a batch sample for process and analytical fit testing. Check for compliance with in-house standards, regulatory expectations, and any specific analytical requirements. Manufacturer batch-specific COA review enables final grade confirmation. Customers typically qualify the sample in their formulation or process before confirming supply scale.
As a producer of p-Hydroxyphenylacetamide, our quality management system aligns with internationally recognized standards for chemical manufacturing. Certification status depends on regional regulatory requirements and client expectations, and documentation can be issued upon request. Core quality management covers every production stage, from raw materials selection to batch finalization. Persistent monitoring of incoming material specifications and batchwise compliance against expected benchmarks forms the backbone of our daily operations. Routine audits enforce risk management practices and corrective actions. Our plant realizes batch consistency through tracked production runs and tightly controlled process parameters; this is reflected in released batch certificates.
Certification requirements for p-Hydroxyphenylacetamide differ according to grade, region, and intended downstream application such as pharmaceutical, photographic, or specialty chemicals. Final product assessment references customer specifications or published industry guidelines, and compliance is evidenced through supporting documentation specific to each batch. Customers seeking custom impurity profiles or end-use suitability evidence receive documentation tailored to the agreed contractual standards.
Every consignment ships with a Certificate of Analysis, detailing compliance with agreed specification ranges and reporting actual measured results for each key parameter. Regulatory support documents—such as manufacturing process statements, non-animal origin declarations, or residual solvent statements—are provided as required for each market or application segment. Long-term clients can request trend analysis reports that summarize batch release data to support audit or due diligence processes. Updates and full traceability records stay available in compliance with the documented retention policies.
We maintain a buffer in core production capacity for p-Hydroxyphenylacetamide to absorb fluctuations in customer demand or unplanned equipment downtime. Contract manufacturing availability, advance reservation, and long-term scheduling are preferred by clients with predictable annual volumes. We respond to short-term inquiries with a transparent assessment of available plant scheduling and committed forward allocation. For recurring needs, we establish rolling delivery schedules that allow both parties to adjust batch sizes and call-offs according to actual project uptake.
Our plant schedules revolve around backward-integrated procurement of critical raw materials, on-hand safety stocks, and preventive maintenance windows. Each lot of p-Hydroxyphenylacetamide is the output of routinized batch production and in-process controls, targeted to maximize yield stability and batch-to-batch reproducibility. Supply capability is assured by redundancy in critical unit operations and the maintenance of pre-qualified secondary raw material sources.
Sample requests are managed directly by our technical and quality staff. Qualification samples are provided according to agreed test quantities, and the specific grade is selected based on the downstream application under evaluation. Documentation delivered with samples includes a test-specific certificate and, where necessary, application notes or product statements tailored to client's technical review requirements. We invite feedback from sampled batches and, if process customization is required, provide updated samples using iterative process adjustments.
Flexible supply agreements typically involve pricing models adjusted for MOQ, lead time, packaging format, and integrated logistics support. Upon review of the client’s formulation or process requirements, technical teams draft adjustment proposals that may involve minor modification to impurity profiles, particle size, or drying conditions. Batch splitting, tailored labeling, and kitted documentation formats are offered for pilot or full-scale production projects, allowing customers to integrate our material into their operation with minimal upstream disruption. Framework agreements are structured for phased ramp-up or seasonal production, ensuring stable access to critical input materials while smoothing cost benchmarks for both parties.
In current industrial R&D, interest centers on process intensification for p-Hydroxyphenylacetamide synthesis, including improvements in catalyst selection and solvent systems. Most grades intended for active pharmaceutical ingredient intermediates demand tight control of aromatic impurities and minimal colored byproduct formation. Continuous flow methods and greener oxidation strategies receive significant attention, as batch-based processes often introduce variable impurity patterns. Manufacturers and technical teams focus on minimizing trace contaminants, especially those approaching regulatory reporting thresholds. The drive to meet downstream purity targets without sacrificing throughput shapes raw material selection and in-line monitoring approaches.
Aside from established pharmaceutical and fine chemical routes, demand rises in performance polymer modification and specialty dye intermediates. Some markets require grades engineered for controlled-release excipient blanks or UV-absorbing functionalities, requiring deeper impurity profiling and process reproducibility. Application specialists note that particular customer segments request modifications in crystal form or particle size distribution, especially for integration into formulation processes sensitive to bulk density and solubility mapping.
Most process challenges involve reducing residual solvents and phenolic byproducts without adding process steps that compromise batch yields. Solvent recovery and recrystallization efficiency tend to be closely watched batch-to-batch, particularly in campaigns where grade-sensitive downstream processes demand exact impurity profiles. Improved chromatographic analysis methods support faster release and tighter feedback control. Significant breakthroughs include the scaling of low-temperature aminolysis steps, improving color stability and shelf-life for critical grades. Process teams work to align purification strategy and product stability with both regulatory and real-world storage conditions, recognizing that observed stability and free-flow characteristics can shift during regional transport and storage cycles.
In the short to mid-term, the global outlook points to increasing demand from advanced pharmaceutical synthesis, particularly for pain management and anti-inflammatory intermediate production. Growth tracks regional regulatory alignment, favoring manufacturers with demonstrated consistency across batches and adaptable impurity control. Tighter scrutiny over supply chain traceability and consistent documentation is expected to raise the entry bar in regulated markets. Downstream customers push for more granular technical support and lot release transparency, influencing the shape of technical documentation and post-shipment queries.
Technical teams prioritize advances in real-time analytical techniques and multi-step synthesis integration, aiming to cut process time and reduce waste generation. Greener process adaptations—particularly solvent minimization and renewable feedstock options—shape investments in process plant upgrades. Facilities expand automation and data capture capacity, supporting end-to-end traceability for sensitive grades. These shifts create real benefits for both initial product quality and long-term stability during storage and transit.
Environmental pressures shift manufacturer priorities toward closed-loop solvent recovery and reduction of hazardous intermediates. Process engineers evaluate renewable feedstock options based on regional availability and supply consistency. Purification methods now include selective adsorbents and membrane filtration, aiming to reduce chemical polishing steps and decrease overall process waste. Batch and continuous process hybridization receives added attention, targeting both energy savings and lower carbon emissions per unit output. Implementation pace depends on product grade, endpoint application, and customer willingness to transition to new sourcing protocols.
Factory-based technical teams provide application-specific support before and after shipment, including analytical testing harmonization and troubleshooting for anomalous test results. Experts routinely deliver impurity breakdowns and processing advice tailored to each product grade and final use scenario. Direct line consultation is available for conversion yield optimization and identification of out-of-spec materials in downstream reactions.
Process specialists partner with customers to tailor material handling, dissolution, and bulk logistics setups, especially for high-purity or formulation-sensitive grades. Advice covers storage conditions, blending sequences, and in some cases, evaporation and recrystallization protocols matched to plant-scale requirements. Continuous feedback loops—especially during new product qualification phases—help adapt standard production release criteria to exact customer specifications, decreasing risk of post-delivery process disruptions.
All manufactured lots leave with traceable documentation connecting batch process parameters, in-process test points, and final release data. Technical support remains available throughout the product lifecycle, addressing both immediate and longer-term stability or performance questions that may arise under varied storage and processing environments. The company undertakes regular audits of support outcomes, using documented field issues to tighten specification windows and adjust batch management controls for future campaigns.
As a chemical producer engaged directly in the manufacturing of p-Hydroxyphenylacetamide, our operations focus on every phase—from raw material sourcing through to final product shipment. Decades of plant experience inform our understanding of market expectations and end-user performance needs. Our production lines run dedicated synthesis campaigns for this compound, supported by process controls and analytical methods that capture both common and subtle quality variables.
This intermediate supports a range of industrial applications. Pharmaceutical developers rely on p-Hydroxyphenylacetamide to build advanced molecules, including certain APIs. In colorants and resin synthesis, our material combines chemical stability with predictable reactivity, supporting both batch and continuous manufacturing setups at scale. The compound meets strict demand cycles in sectors such as dyes, agricultural intermediates, and specialty chemicals.
Our commitment to batch integrity has grown from years of process optimization. We design process flows to minimize batch-to-batch variability, controlling everything from reaction temperatures and pH adjustments to material handling protocols. In-house analytics validate product identity, purity, and trace-level contaminants. Each production batch receives full documentation, including certificate of analysis prepared and signed off by our plant technical staff.
All p-Hydroxyphenylacetamide leaving our facilities undergoes packaging under strictly monitored conditions. We offer a choice of multi-layer bags, fiber drums, and lined barrels, targeting moisture and contamination risks throughout the supply chain. High-volume packaging automation ensures load efficiency for bulk buyers, while our export logistics team tracks every shipment for origin assurance and transit security. Our inventory planning aligns with forecasted demand, ensuring buyers have access to product on a just-in-time basis and for recurrent contract supply.
We view technical support as an extension of production, not as a post-sale service. Our process engineers and chemists collaborate with buyers on raw material compatibility, method validation, and production line integration. Troubleshooting covers scale-up guidance, filtration, and crystallization—based on real-world plant feedback. This dialogue has helped several partners upgrade processes, optimize formulations, and resolve on-site technical bottlenecks.
Our direct manufacturing control shortens lead times and supports fixed specification deliveries for industrial and commercial buyers. Long-term relationships with downstream manufacturers and trading partners result from fewer supply interruptions and transparent lot histories. Procurement managers benefit from predictable quality, custom packaging, and cooperative delivery scheduling supported by our own logistics and documentation teams. Transparent production and documentation practices also support regulatory reporting, import clearances, and third-party audits.
Serving as the actual producer positions us to understand both process realities and changing market demands. Delivering value in p-Hydroxyphenylacetamide supply starts with our operations and continues across all points of buyer interaction—from initial discussions to ongoing technical and logistical support.
At our manufacturing facility, every batch of p-Hydroxyphenylacetamide goes through rigorous purification and quality assurance procedures. Chemical purity stands as a primary concern throughout production. For our clients in pharma, research, and the wider specialty chemical sector, we recognize the consequences of even minor impurities. Not only can off-spec batches interrupt a client’s own processes, but even trace contaminants will often compromise analytical results or downstream synthesis. Our responsibility as the original manufacturer is to guarantee confidence in every lot shipped.
In regular production runs, our typical assay values for p-Hydroxyphenylacetamide consistently meet or exceed 99%. We achieve this level through a multi-stage purification sequence that culminates in thorough final product testing, using both HPLC and suitable spectroscopic methods. Data on each batch remains traceable so clients can always reference the documented analysis for their specific lot. We have learned over the years that transparency and rigorous documentation prevent most common concerns before they occur.
Some applications, especially in regulated environments, demand extremely narrow purity ranges. Our experience supplying raw materials to pharmaceutical firms and research institutions has made it clear that even one-tenth of a percentage point can mean the difference between approval and rejection for a formulation or study. For this reason, our finished product specification typically requires an assay (by HPLC) not less than 99.0%. We also run stringent checks for moisture, heavy metals, related compounds, and ash content, each monitored by validated methods to ensure compliance with global reference standards.
Oversight does not end at the assay. Trace byproducts and process impurities require equal scrutiny. With modern detection technologies, we routinely check for related substances down to low ppm levels. Every production change, whether a solvent swap or improved filtration step, passes through our in-house validation to guarantee that no unintended contaminants are introduced. Our technical team is keenly aware that each client application drives new requirements; as a direct manufacturer, we routinely adapt batch records and test parameters to support unique requests, always aligning with project goals and regulatory needs.
Lab analysis forms just one link in the chain. From raw material sourcing through finished product packaging, every kilogram of p-Hydroxyphenylacetamide ships with full batch-level documentation. Chain-of-custody records, production logbooks, instrument calibrations—all remain available for audits or customer technical reviews. We train our technical staff not just to run the instruments but to understand where upstream impurities could sneak through, and to intervene well before product ever leaves our site.
Our documentation supports stringent internal audits and helps end users reduce risk on their side. For any batch, we can provide detailed specifications, analytical methods, and stability data.
Staying ahead of evolving purity requirements is a task we take seriously. Innovations in regulatory science and end-user applications regularly push purity expectations higher. Our quality system emphasizes active process improvement, driven by both external feedback and internal reviews. If clients identify new analytical needs—such as lower detection limits for specific impurities—we respond by upgrading our detection methods or custom tailoring lot-specific test plans. That’s how we support critical applications across pharma, advanced materials, and custom synthesis, remaining a committed, technically capable manufacturer in the specialty chemicals sector.
Consistent access to p-Hydroxyphenylacetamide in bulk is essential for a range of client operations, from pharmaceutical synthesis to intermediate production for various specialty applications. On our production lines, we manage high-capacity syntheses throughout the year, which allows us to fill both standard orders and large-scale contracts reliably. Our raw material sourcing, process engineering, and in-house quality controls keep supply stable, especially for businesses that build medium to long-term operational plans around critical chemicals like para-hydroxyphenylacetamide.
Bulk buyers depend on straightforward logistics and clear pack sizing. For p-Hydroxyphenylacetamide, our standard packaging includes:
Every pack carries batch labels, manufacturing dates, and tamper-evident seals directly applied on our filling line. We use heavy-duty external drums and sacks tested for stability and moisture resistance during long shipments. This approach helps prevent product caking, contamination, or loss of material integrity, which are common issues during bulk storage or extended transit. For regions with special shipping or handling requirements, our logistics team coordinates packaging modifications that comply with customer safety standards, but the same product quality is always maintained.
Clients in regulated industries expect rigorous, traceable quality with every package—factors we control through batch-level documentation and in-house analytical checkpoints. Our technical staff monitors key physical properties such as purity, particle size, and residual moisture, and our team prepares full COA documentation for each bulk shipment. Because we hold direct responsibility for every step, from process design and scale-up to packaging and dispatch, any technical support can be provided quickly with information from our production team.
Meeting bulk demand also means adapting to evolving industry needs. For example, we have refined our packing line to offer both powder and fine granular forms, since some downstream processes are sensitive to flowability or dusting. Over time, we’ve also improved our packing procedures so customers can quickly empty and dose materials in automated or manual setups.
Our factory inventories are mapped in real time, so we're able to synchronize output even for just-in-time delivery arrangements. Because of our direct manufacturing control, we handle both full-container load orders and smaller urgent shipments directly through our central dispatch. No third-party warehouse or offsite facility comes into play, and this direct pipeline prevents gaps between production and delivery.
As a manufacturer, we prioritize clear communication and transparency on bulk product availability, pack sizes, and fulfillment timelines. Customers can expect a straightforward process: prompt response to volume queries, technical support for pack choice, and routine fulfillment of both contract and spot bulk orders. Our focus always stays on keeping customers supplied with the highest quality p-Hydroxyphenylacetamide, on schedule and in the most appropriate pack size for their process.
As the team directly behind the synthesis and packaging of p-Hydroxyphenylacetamide, we approach storage, transport, and compliance from a practitioner’s perspective. This intermediate finds regular application across pharmaceutical and fine chemical production, which places us under direct scrutiny from regulatory authorities and customer auditors alike.
At our production sites, we store p-Hydroxyphenylacetamide in tightly sealed containers using packaging specifically selected for chemical compatibility and moisture resistance. The material should stay in a cool, dry area with adequate ventilation. We isolate it from strong oxidizers and direct sunlight. Warehouse staff rely on rigorous housekeeping and labeling to prevent cross-contamination. These measures do not stem only from abstract safety protocols; over the years, even a brief lapse in humidity control can affect purity levels or compromise downstream handling. Every batch gets regular inspection, and any packaging with signs of tampering or exposure gets pulled before it ever leaves our storage.
Our logistics schedule favors secured, labeled containers with transport documentation compliant to international guidelines. During transshipment or export, we label drums and bulk bags in accordance with shipment regulations and affix GHS hazard symbols where required. Vehicles get loaded in a way that prevents shifting or ruptures. All shipments include detailed shipping documents with hazard notices attached when the receiving country demands it. Our packaging options support sea, air, and road – a flexibility achieved by using standardized industrial containers, so customers do not face surprises at import clearance.
We keep our production and export process fully aligned with REACH registration when shipping into Europe. Our regulatory reporting provides tracking from raw material intake through production and delivery. For GHS, we classify this molecule as a substance that may pose a minor hazard profile – commonly “H” coded, such as eye irritation if handled improperly, for example. Our safety data sheets reference the latest GHS revision for hazard symbols and precautionary statements, and our technical team updates these sheets in response to regulatory changes or customer audit feedback.
Regular batch analysis and archiving ensure every kilogram shipped traces back to raw input and synthesis log. This level of documentation stands as a requirement under both REACH and other national frameworks, so customers avoid any compliance interruptions. By maintaining registration under the necessary inventories, we ensure our product does not encounter hold-ups at customs or local regulatory offices.
Handling p-Hydroxyphenylacetamide safely goes beyond ticking boxes on a checklist. Our teams have witnessed firsthand how temperature spikes in unmonitored warehouses or broken seals during transit can create issues for downstream formulations, not just regulatory headaches. Every storage drum and tanker leverages our decades of in-plant experience, which adds real substance behind the compliance declarations. Our goal is not only to meet the government minimum but to exceed industry expectations by delivering consistent material performance, every shipment, every batch. Customers return to us for this reliability, rather than rely on secondhand assurances.
For product inquiries, sample requests, quotations or after-sales support, please feel free to contact me directly via sales9@alchemist-chem.com, +8615651039172 or WhatsApp: +8615651039172
